Synthesis of novel pyrimidine-based Schiff base complexes: Targeting Amyloid-(3 aggregation in Alzheimer's disease

A novel Schiff base with imine/amine donors, 5-((3,3-diphenylalilidene)amino)pyrimidine-4-amine (L), and its new Platinum(II) and Ruthenium(II) complexes (I and II) were synthesized and characterized using FT-IR, 1H NMR, 13C NMR, mass spectrometry and elemental analyses. The ability of these complexes to inhibit amyloid beta (A(31_42) aggregation was evaluated using the human neuroblastoma cell line (SH-SY5Y). The complexes effectively inhibited A(31_42 aggregation at a 1:1 M ratio. Both complexes increased cell viability up to 80 % at concentrations of 10 mu M. At this concentration, the cell viability value found by A(31_42 aggregation is around 65 %. Aggregation kinetics were fluorometrically monitored using Thioflavin T. These findings were further supported by scanning electron microscopy and transmission electron microscopy. In addition, the interaction of the complexes with A(31_16 was investigated using MALDI-TOF/MS and 1H NMR spectroscopy. All findings showed that A(31_42 in both complexes is active in the inhibition of amyloid aggregation.